New funding to strengthen Cuba's biopharmaceutical industry

Home/Pharma News | Posted 18/11/2022 post-comment0 Post your comment

On 22 September 2022, the United Nations Development Programme (UNDP) announced the execution of a loan of Euros 46.7 million (US$45.25 million dollars) to support Cuba's biopharmaceutical industry and improve the country's capacity to respond against diseases such as COVID-19.

Meds Cost Euros 1 V13L06

The credit, signed by the Central American Bank for Economic Integration (CABEI), also includes the reinforcement of the productive infrastructure for the production of injectable antibiotics, parenteral solutions (serums), generic and biosimilar medicines, diagnostics and medical equipment used in the treatment of people infected with COVID-19 and other communicable diseases, as well as the acquisition of health supplies and medical protection material to prevent contagion. 

The initiative, which will benefit more than 11 million people through the production of 200 million doses of vaccines, is expected to achieve higher levels of economic productivity through the development of innovative medicines of great importance in the context of the pandemic and the modernisation of technology, which will contribute to diversification for the benefit of the national health system and other Latin American countries.

In addition to the million-dollar loan from the UNDP to develop medicines, there are actions by Cuban authorities to expand international cooperation in this area. An Action Plan for the period 2023–2025 was recently signed between the health authorities of Cuba and Vietnam with the aim of both countries to advance in pharmaceutical and biotechnological cooperation, as well as to strengthen existing partnerships in the area of biopharmaceuticals and promote their development.

Cuba has been suffering a long crisis, even before the appearance of COVID-19, due to the lack of raw materials and the instability of supplies to produce medicines, many of which are indispensable, especially for the treatment of chronic diseases for a large part of the population.

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Hechos clave en la regulación de la aprobación de biosimilares en Brasil

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Hechos clave en la regulación de la aprobación de biosimilares en Brasil

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

Related articles
COVID-19 vaccine produced in Latin America

Regulations of the registration of biosimilars in Latin America

Biosimilars approved in Cuba

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved

comment icon Comments (0)
Post your comment
Related content
New partnerships: Biocon-Yoshindo and Syna-Intas
19 AA010921
Home/Pharma News Posted 25/11/2022
GaBI news digest for 14 October 2022
56 AA011042
Home/Pharma News Posted 14/10/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010